摘要:
Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.
摘要:
The present invention relates to a maternal nutrition composition comprising myo-inositol and probiotics. Such a composition has been specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman and/or to a lactating woman. The invention also relates to the use of a combination of myo-inositol and one or more probiotic for use to minimise excessive fat accretion in a pregnant subject or a subject desiring to become pregnant, and/or to treat or prevent gestational diabetes mellitus and conditions associated therewith in a pregnant subject and/or its offspring, wherein said combination of myo-inositol and one or more probiotic is administered to said subject before and/or during pregnancy and/or during lactation.
摘要:
Myo-inositol and one or more probioticfor use to improve insulin sensitivity and/or treat or prevent type II diabetes and/or to prevent CVD and/or a condition associated with a low insulin sensitivity and/or any of the foregoing in a subject.
摘要:
A method of preparing nutritionally fortified yeast comprising: a) incubating yeast with at least one fermentable substrate under conditions suitable for achieving fermentation; b) isolating the yeast after fermentation; c) combining the isolated yeast with at least one micronutrient selected from vitamins, minerals, amino acids and antioxidants to obtain nutritionally fortified yeast; and d) drying the nutritionally fortified yeast. The method allows high levels of micronutrient retention by the yeast such that the nutritionally fortified yeast obtained by the method is a useful vehicle for supplementing foods with micronutrients.
摘要:
The present disclosure relates to a lipid source for nutritional compositions, comprising an enriched lipid fraction which comprises structured fat globules. The enriched lipid fraction provides fat globules having a desired size and fatty acid composition and may be stabilized by components such as phospholipids, cholesterol, milk-fat globule membrane protein and combinations thereof. Additionally, the disclosure relates to methods of supporting lipid digestion in a pediatric subject by providing a nutritional composition comprising an enriched lipid fraction having structured fat globules that are more accessible to lipases. The chemical composition, size and structure of the fat globules may improve digestion. The disclosed nutritional compositions may provide additive and or/synergistic beneficial health effects.
摘要:
There are provided nutritional compositions. In one embodiment a nutritional composition comprises: carbohydrate; a carnitine component; and one or more components selected from the group consisting of: a lipoic acid component; a sodium compound; a choline component; a green tea component; and a catechin component. Also provided are packaged nutritional products and the use of nutritional compositions.
摘要:
An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
摘要:
A composition comprising (a) one or more ω-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350 ng Total-tau per litre cerebrospinal fluid (CSF), and a weight ratio of abeta- 42/ Phospho-tau-181 of less than 6.5 in CSF.
摘要翻译:一种组合物,其包含(a)一种或多种选自DHA,DPA和EPA的α-3脂肪酸,(b)尿苷或其等同物,和(c)可用于治疗具有前驱物特征的人的甲基供体 痴呆病人 特征包括例如 每立方英尺脑脊液(CSF)超过350 ng Total-tau的水平,CSF中abeta- 42 / Phospho-tau-181的重量比小于6.5。
摘要:
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a/ a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b/ a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
摘要翻译:现在已经发现,在给患有发展这种疾病的危险的患病个体或个人之后,该药物或药物组合物包含包含二十二碳六烯酸(DHA),二十二碳五烯酸(DPA)中的至少一种的脂质部分 )和二十碳五烯酸(EPA); b /一种蛋白质级分,其包含至少提供半胱氨酸和/或牛磺酸的来自非人源的蛋白质物质; 和c / a包含锰和钼中的至少一种的矿物部分,这些人的健康得到改善。 几种类型的哺乳动物细胞的膜功能得到改善,其允许有效治疗免疫相关疾病,例如过敏,自身免疫性疾病,癌症,认知功能障碍和其他神经系统疾病,神经病,如糖尿病性神经病和神经性疼痛,神经元损伤 在胰岛素抵抗期间,肠道疾病和支持生长或恢复期间肠和肺功能的发展。